Nearly a third of positional sleep apnea patients didn't need the therapy, or failed it
A home-monitoring trial found some patients don't sleep on their backs at home the way they did during their diagnostic sleep study, while others simply failed the vibrating device meant to keep them off their backs.
Positional obstructive sleep apnea (POSA) — where breathing interruptions occur mainly when a person sleeps on their back — is the most common sleep apnea phenotype, and positional therapy devices designed to discourage back-sleeping are a widely used treatment. But patient selection for this therapy has remained imprecise, according to a study published this month in Sleep Medicine, which set out to quantify exactly how often positional therapy either isn't needed or doesn't work [s1].
The design
Researchers conducted a retrospective observational study of consecutive adults diagnosed with positional obstructive sleep apnea at a tertiary sleep center between 2021 and 2024 [s1]. All patients underwent a home-based trial using a neck-worn vibrotactile positional therapy device (Night Shift), which included a monitoring-only phase followed by an active therapy phase [s1]. The study tracked what proportion of patients didn't habitually sleep on their backs at home in the first place (making positional therapy unnecessary for them), and what proportion failed the device despite being appropriate candidates [s1].
What it found
Of 92 screened patients, 74 met inclusion criteria, with a mean age of 60.3 and mean apnea-hypopnea index of 22.9 events per hour [s1]. Fifteen percent (11 of 74) did not habitually sleep on their backs at home during the monitoring phase — meaning they had no real clinical need for positional therapy in the first place, despite their initial POSA diagnosis [s1]. A further 14.8% (11 of 74) failed the vibrotactile positional therapy device despite being appropriate candidates for it [s1]. Combined, 30% of patients — nearly a third — were either unlikely to benefit from positional therapy or failed it outright [s1]. Non-response to the device was frequently associated with use of psychotropic or sedative medications and with neurological or sleep-related comorbidities [s1].
Why the gap between the sleep-lab diagnosis and home behavior matters
The core problem this study identifies is a mismatch between how someone sleeps during a single-night, in-lab or monitored diagnostic sleep study — where they're diagnosed as position-dependent — and how they actually sleep at home over multiple nights in their own bed. A diagnostic study capturing one night's sleep position pattern doesn't necessarily predict someone's habitual sleep position across many nights at home, and this study's home-monitoring phase is specifically designed to catch that discrepancy before committing a patient to ongoing positional therapy they may not actually need.
Why the psychotropic and sedative medication association is a useful clue
The finding that non-response to positional therapy clustered among people using psychotropic or sedative medications, or with neurological or sleep-related comorbidities [s1], points toward a plausible mechanism: these medications and conditions can affect how deeply someone sleeps, how much they naturally shift position during the night, or how responsive they are to a vibrotactile cue prompting a position change — meaning the device's core mechanism (nudging a sleeping person to reposition) may be less effective in people whose sleep is already altered by other medications or conditions.
What this doesn't establish
This is a retrospective, single-center observational study of a specific vibrotactile device (Night Shift), and results may not generalize to other positional therapy devices with different mechanisms, or to patients evaluated at other centers with different diagnostic protocols. The study doesn't report longer-term outcomes beyond the home-based trial period, so it doesn't establish what happens to patients identified as unlikely to benefit or as treatment failures once they're redirected to alternative therapies. The specific reasons why psychotropic or sedative medication use predicted device failure aren't tested directly, only observed as an association.
What the authors recommend
The study's authors argue that incorporating a brief home-monitoring and therapy trial into routine clinical practice — rather than committing directly to long-term positional therapy based on a single diagnostic night — could optimize patient selection, reduce unnecessary costs, and improve personalized management of positional sleep apnea [s1], a practical recommendation grounded directly in the 30% mismatch rate this study documents.
What to watch
Whether this home-monitoring screening approach gets more widely adopted in clinical practice, and what alternative treatments prove most effective for the substantial minority of patients this study identifies as unlikely to benefit from positional therapy. This article is not medical advice.
Sources
Sources
More on
Most snoring is harmless. What quiets it depends on why you snore
The remedies that work are the ones matched to the cause — nose, mouth, tongue or palate. Here is what the trials support, and the sign that means see a doctor first.
Titan and Breathe Right nasal strips, compared — and where mouth tape fits
Both brands sell drug-free external nasal dilators with much the same evidence behind them. The differences are range, materials, and the fact that only one also sells a mouth tape.
Not the oxygen drops: broken sleep tracked with depression, insomnia explained it
In 1,238 people from two community cohorts, apnea severity showed no link to depressive symptoms. Sleep fragmentation did, and that association disappeared once insomnia symptoms entered the model.
A smartwatch matched the sleep lab on severe apnea. The threshold is the catch.
In 152 adults tested against two nights of polysomnography, the Galaxy Watch reached an AUROC of 0.94 for moderate-to-severe sleep apnea — with 66.7% specificity at the setting it ships with.